Compare BSL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSL | BDSX |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.3M | 153.3M |
| IPO Year | N/A | 2020 |
| Metric | BSL | BDSX |
|---|---|---|
| Price | $12.95 | $22.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 36.6K | ★ 67.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $12.45 | $0.33 |
| 52 Week High | $14.35 | $24.92 |
| Indicator | BSL | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 60.22 |
| Support Level | $12.83 | $19.00 |
| Resistance Level | $12.94 | $24.92 |
| Average True Range (ATR) | 0.07 | 1.72 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 7.41 | 65.36 |
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.